Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 977

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 3
Chunk 977
---
 by the Company for his services as a director. In connection with his appointment,
Mr. Kim has entered into a Letter Agreement and an Indemnity Agreement with the Company on the same terms as the Letter Agreement
and Indemnity Agreement entered into by the directors and officers of the Company at the time of the Company’s initial public offering
and in the form previously filed as Exhibits 10.1 and 10.6, respectively, to the Company’s Annual Report on Form 10-K filed
with the SEC on April 17, 2024. Other than the foregoing, Mr. Kim is not a party to any arrangement or understanding with any
person pursuant to which he was appointed as director, nor is he party to any transactions required to be disclosed under Item 404(a)
of Regulation S-K involving the Company.

As previously disclosed on the Company’s Current Report filed
on Form 8-K on March 25, 2025, on March 24, 2025 the Company Board appointed Dr. Constance Höfer as the Company’s Chief
Scientific Officer, effective on that date. Dr. Höfer is a seasoned leader in drug development with over 20 years of experience in
oncology and immunology and will oversee the Company’s scientific strategy and innovation pipeline.. Coupled with her extensive
industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology
and translational medicine, ensuring a seamless transition from early-stage research to successful clinical development.

In connection with Dr. Höfer’s appointment, the Company
entered into an employment agreement (the “Agreement”) with Dr. Höfer, which provides for her compensation
and other employment terms. Under the Agreement, Dr. Höfer will receive:

●A base salary of $300,000.00
per year;

●Participation in Equity-based
Compensation Plan of the Company, as determined at the discretion of the Company’s Compensation Committee; and

●Other customary benefits available
to executive officers of the Company.

There are no arrangements or understandings between Dr. Höfer
and any other person pursuant to which she was selected as an officer. Additionally, Dr. Höfer does not have any family relationships
with any director or executive officer of the Company. Further, Dr. Höfer has no related-party transactions reportable under Item
404(a) of Regulation S